- Home
- WLTH vs PCRX Comparison
WLTH vs PCRX Comparison
Compare WLTH & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WLTH | PCRX |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | WLTH | PCRX |
|---|---|---|
| Price | $8.03 | $22.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $12.86 | ★ $37.60 |
| AVG Volume (30 Days) | ★ 1.2M | 801.0K |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $16.04 | $9.77 |
| Revenue Next Year | $24.89 | $9.71 |
| P/E Ratio | ★ $10.57 | $138.44 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $7.20 | $18.80 |
| 52 Week High | $14.12 | $27.99 |
Technical Indicators
Market Signals| Indicator | WLTH | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 52.21 |
| Support Level | $7.25 | $20.41 |
| Resistance Level | $9.32 | $23.91 |
| Average True Range (ATR) | 0.54 | 1.00 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 40.61 | 54.08 |
Price Performance
Historical ComparisonAbout WLTH Wealthfront Corporation Common Stock
Wealthfront Corp is a technology company that built a financial solutions platform for digital natives. Its platform is designed to address the needs of the wealth builders within these generations.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.